NVAX

#1794
Novavax Inc
10.14
-9.14%
Secteur:
Base:
Devise de Profit:
Range quotidien
10.14
10.14
Range Annuel
5.01
11.97
Changement quotidien
-9.14%
Changement Mensuel
+4.11%
Evolution sur 6 mois
+30.84%
Changement Annuel
+41.42%
Clôture Précédente
11.16
Open
10.14
Bid
Ask
Low
10.14
High
10.14
Volume
187
Open full chart

Financials

Overview Relevé Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.65 B
  • Employee 1 992
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
2.6
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Nouvelles